Recent studies demonstrated that knockdown of SPRY2 enhances CD44 in cancer-associated fibroblasts, whereas knockdown of SPRY1 reduces stemness of patient-derived glioma stem cell spheres [74,75]. This evidence concerns the gene SPRY1 and central nervous system cancer.